Category

In the News

Dr. Joshua Grill discusses A4 Study results in Alzforum

By | Carousel Slider, Commentary, In the News | No Comments

This week Alzforum posted coverage from the Alzheimer’s Association International Conference, including UCI MIND Director Dr. Joshua Grill’s presentation of data from The A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease Study). In The A4 Study, a secondary prevention trial of late-onset Alzheimer’s disease, people with elevated amyloid had higher levels of memory complaints than those without elevated amyloid. To read the full article, click here > 

Read More

Orange Coast Magazine calls upcoming conference a “Can’t-Miss” health event in OC

By | Carousel Slider, Community Events, In the News | No Comments

Orange Coast Magazine​ just named our upcoming research conference in the “20 Can’t-Miss Health Events in O.C. To Keep You Healthy!” Don’t miss your chance to attend Trials Today, Treatments Tomorrow, Sept. 21 at the Irvine Marriott​. Tickets: http://bit.ly/alzconference or call 949.757.3720 x 3733. “Alzheimer’s affects more than 84,000 people in Orange County. This conference, hosted by the UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND) and Alzheimer’s Orange County, will bring world-renowned experts to Irvine to discuss progress in the battle against Alzheimer’s.” — Orange Coast Magazine  

Read More

UCI MIND needs volunteers for clinical trials on Alzheimer’s disease

By | Carousel Slider, In the News | No Comments

UCI MIND Director Dr. Joshua Grill wrote an article for the Daily Pilot about the need for Alzheimer’s clinical trial research participants in Orange County. Read an excerpt below, and click here for the full article > “Here in Orange County, we are home to the Alzheimer’s Disease Research Center, the UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND). And we are making progress. There will be one essential key to needed advances, however. You. We need more people to participate in research, especially clinical trials of promising treatments. Clinical trial participants in Alzheimer’s research, much like…

Read More

New York Times article breaks down barriers to recruitment and brings hope with a new trial

By | Commentary, In the News | No Comments

The New York Times recently covered a new clinical trial effort Eli Lilly is undertaking, the TRAILBLAZER-ALZ clinical research study. The study, which UCI MIND investigators are participating in, aims to enroll 375 people with early Alzheimer’s disease. To learn more about the TRAILBLAZER-ALZ study, click here, or contact us at research@mind.uci.edu or call 949.824.0008.

Read More

UCI Researchers awarded grant to explore gender differences in Alzheimer’s

By | Commentary, In the News | No Comments

Currently, 2 out of every 3 people with Alzheimer’s disease are women. Last year, UCI MIND began a partnership with Maria Shriver’s Women’s Alzheimer’s Movement. This partnership launched a grant competition focused on understanding the role of sex in Alzheimer’s disease. UCI researchers Sunil Gandhi and Mathew Blurton-Jones have been awarded this year’s $100,000 grant. Their research will focus on the role of microglia in the brains of men and women using induced pluripotent stem cells generated from skin cells donated by UCI ADRC participants, modern mouse models of the disease, and cutting edge microscopy techniques. To learn more >

Read More

We’re happy to hear good news, but we still need to see the data

By | Commentary, In the News | No Comments

This week, BioArctic Neuroscience, Esai, and Biogen made headlines when they announced via press release the topline and positive results of their Phase 2a study of the anti-amyloid antibody BAN2401. The press release indicated that the drug “demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain” in patients with early Alzheimer’s disease. To be sure, this is welcomed news. Too often headlines for Alzheimer’s disease clinical trials are about “flops” and “failures.” So we should take this good news and embrace it. Unfortunately, there remain many questions to which we need answers before we…

Read More

Remembering the contributions of Nobel laureate Dr. Arvid Carlsson in the field of Parkinson’s disease

By | In the News | No Comments

Dr. Arvid Carlsson passed away this past Friday at the age of 95. His research into dopamine led to the development of treatments for Parkinson’s disease, a neurodegenerative disease that involves tremors and rigidity. Dr. Carlsson showed that dopamine was a neurotransmitter and that it is critical to movement. Dopamine is depleted in Parkinson’s disease and the drug L-dopa can be used to treat patients with this neurological disease. Dr. Carlsson’s findings earned him the 2000 Nobel Prize in Physiology or Medicine, along with noted American researchers Dr. Eric Kandel and Paul Greengard. UCI MIND is grateful for the work…

Read More